Sewerynek J, Wiktorska J, Nowak D, Lewinski A
Department of Thyroidology, Institute of Endocrinology, Lodz, Poland,
Endocr Regul. 2000 Jun;34(2):83-9.
To examine the dynamics of oxidative stress in patients with hyperthyroidism before and during the treatment with methimazole using the measurement of conjugated dienes, malondialdehyde, and Schiff bases in blood serum.
In eight female patients with diagnosed Graves disease and 8 healthy control subjects (7 females and one male) several parameters of oxidative stress (the level of conjugated dienes [CD], malondialdehyde [MDA] and Schiff bases [SB]) were estimated before and during the treatment with methimazole (Metizol -POLFA) as well as by hormonal and immunological tests. In addition, serum levels of TSH, free thyroxine (FT4), free triiodothyronine (FT3), antibodies against thyroperoxidase (anti-TPO) and thyroglobulin (anti-Tg) and low density lipoprotein-cholesterol fraction (LDL-Ch) were estimated.
We observed increased concentrations of free thyroxine (FT4) and free triiodothyronine (FT3), as well as of antithyroperoxidase (anti-TPO) and antithyroglobulin (anti-Tg) antibodies. At the same time, TSH level was significantly suppressed. The concentrations of thyroid hormones and of TSH normalised after the methimazole treatment. The examined parameters, i.e., CD, MDA, and SB, were evaluated as proportions of each of them to the level of low density lipoproteins-cholesterol fraction (LDL-Ch). This fraction of cholesterol contains many polyunsaturated fatty acids, being a substrate for the peroxidation of lipids. Additionally, the CD/MDA ratio was calculated.
The increase of the CD/LDL ratio in Graves hyperthyroidism and its normalisation in the course of the treatment with methimazole suggests that the drug can be protective against the oxidative stress induced by overproduction of thyroid hormones. The ratio of CD/MDA decreased in all the patients, as compared to the control group, showing a high speed of lipid peroxidation.
通过测定血清中共轭二烯、丙二醛和席夫碱，研究甲亢患者在使用甲巯咪唑治疗前及治疗期间氧化应激的动态变化。
选取8例诊断为格雷夫斯病的女性患者和8名健康对照者（7名女性和1名男性），在使用甲巯咪唑（美替唑 - 波拉法）治疗前及治疗期间，通过激素和免疫学检测评估氧化应激的几个参数（共轭二烯[CD]、丙二醛[MDA]和席夫碱[SB]水平）。此外，还测定了血清促甲状腺激素（TSH）、游离甲状腺素（FT4）、游离三碘甲状腺原氨酸（FT3）、抗甲状腺过氧化物酶抗体（抗 - TPO）、抗甲状腺球蛋白抗体（抗 - Tg）以及低密度脂蛋白胆固醇组分（LDL - Ch）的水平。
我们观察到游离甲状腺素（FT4）、游离三碘甲状腺原氨酸（FT3）以及抗甲状腺过氧化物酶（抗 - TPO）和抗甲状腺球蛋白（抗 - Tg）抗体的浓度升高。同时，TSH水平显著降低。甲巯咪唑治疗后甲状腺激素和TSH浓度恢复正常。所检测的参数，即CD、MDA和SB，以它们各自与低密度脂蛋白胆固醇组分（LDL - Ch）水平的比例进行评估。该胆固醇组分含有许多多不饱和脂肪酸，是脂质过氧化的底物。此外，还计算了CD/MDA比值。
格雷夫斯甲亢患者中CD/LDL比值升高，而在甲巯咪唑治疗过程中该比值恢复正常，这表明该药物可保护机体免受甲状腺激素过度产生所诱导的氧化应激。与对照组相比，所有患者的CD/MDA比值均降低，表明脂质过氧化速度较快。
